Virginia 2023 Regular Session

Virginia Senate Bill SB1415

Introduced
1/11/23  
Refer
1/11/23  
Report Pass
1/19/23  
Report Pass
1/31/23  
Engrossed
2/2/23  
Refer
2/13/23  
Report Pass
2/14/23  
Refer
2/14/23  
Report Pass
2/15/23  
Enrolled
2/23/23  
Chaptered
3/26/23  

Caption

Opioids; impact reduction registry, report.

Impact

The introduction of SB1415 is expected to have significant implications for state legislation regarding healthcare and drug policies. By requiring the Department of Health to evaluate and streamline existing naloxone distribution programs, the bill seeks to improve the availability of this life-saving medication in high-risk areas. In addition, it emphasizes collaboration among various state departments and local organizations to ensure effective distribution and access to naloxone, which could reduce opioid overdose deaths significantly.

Summary

SB1415, also known as the Opioid Impact Reduction Registry Bill, aims to implement a comprehensive strategy for reducing the impact of opioid misuse across the state. The bill proposes the establishment of a statewide opioid impact reduction registry that lists nonprofit organizations working to combat opioid addiction and provides crucial support services. This registry is intended to enhance public access to resources and information regarding opioid-related assistance and services available throughout the commonwealth. The Department of Health will oversee the development of this registry and ensure that it is user-friendly and accessible to the public.

Sentiment

The sentiment surrounding SB1415 has generally been positive, with many stakeholders expressing support for initiatives aimed at combating the opioid crisis. Proponents view the bill as a necessary step towards more comprehensive and coordinated efforts to address opioid misuse and related fatalities. However, there are concerns about the adequacy of funding and resources to support the proposed initiatives, which some critics argue could undermine the bill’s overall effectiveness.

Contention

One notable point of contention in discussions around SB1415 is the balance between state oversight and local autonomy in executing naloxone distribution programs. While some members advocate for a centralized approach to maximize impact, others fear that local communities may not have the necessary flexibility to address specific needs effectively. As the state moves forward with implementing the provisions of the bill, debates surrounding these governance issues will likely continue.

Companion Bills

No companion bills found.

Similar Bills

VA HB1637

Opioid antagonists; dispensing and administration by person acting on behalf of an organization.

VA SB790

Opioid antagonists; dispensing and administration by person acting on behalf of an organization.

VA SB1035

Opioid antagonists; dispensing and administration by person acting on behalf of an organization.

VA SB1257

Student & campus safety; opioid antagonist administration training for resident assistants required.

VA HB342

Naloxone or other opioid antagonists; possession by state agencies, guidelines for private employer.

VA HB1447

Controlled substances; administration by emergency medical providers.

VA SB1426

Controlled substances; administration by emergency medical providers.